News publications and other organizations are encouraged to reuse Direct Relief-published content for free under a Creative Commons License (Attribution-Non-Commercial-No Derivatives 4.0 International), given the republisher complies with the requirements identified below.

When republishing:

  • Include a byline with the reporter’s name and Direct Relief in the following format: "Author Name, Direct Relief." If attribution in that format is not possible, include the following language at the top of the story: "This story was originally published by Direct Relief."
  • If publishing online, please link to the original URL of the story.
  • Maintain any tagline at the bottom of the story.
  • With Direct Relief's permission, news publications can make changes such as localizing the content for a particular area, using a different headline, or shortening story text. To confirm edits are acceptable, please check with Direct Relief by clicking this link.
  • If new content is added to the original story — for example, a comment from a local official — a note with language to the effect of the following must be included: "Additional reporting by [reporter and organization]."
  • If republished stories are shared on social media, Direct Relief appreciates being tagged in the posts:
    • Twitter (@DirectRelief)
    • Facebook (@DirectRelief)
    • Instagram (@DirectRelief)

Republishing Images:

Unless stated otherwise, images shot by Direct Relief may be republished for non-commercial purposes with proper attribution, given the republisher complies with the requirements identified below.

  • Maintain correct caption information.
  • Credit the photographer and Direct Relief in the caption. For example: "First and Last Name / Direct Relief."
  • Do not digitally alter images.

Direct Relief often contracts with freelance photographers who usually, but not always, allow their work to be published by Direct Relief’s media partners. Contact Direct Relief for permission to use images in which Direct Relief is not credited in the caption by clicking here.

Other Requirements:

  • Do not state or imply that donations to any third-party organization support Direct Relief's work.
  • Republishers may not sell Direct Relief's content.
  • Direct Relief's work is prohibited from populating web pages designed to improve rankings on search engines or solely to gain revenue from network-based advertisements.
  • Advance permission is required to translate Direct Relief's stories into a language different from the original language of publication. To inquire, contact us here.
  • If Direct Relief requests a change to or removal of republished Direct Relief content from a site or on-air, the republisher must comply.

For any additional questions about republishing Direct Relief content, please email the team here.


Issues & Solutions

Direct Relief partners with leading healthcare companies to provide life-saving Factor VIII and Factor IX therapies to help at-risk hemophilia patients.

In Brief

Hemophilia A occurs in 1 in 5,000 live male births, and is a genetic disorder in which blood doesn’t clot normally. The disease has no cure, but treatment can help patients lead full, healthy lives.

The two main forms are hemophilia A (Factor VIII deficiency) and hemophilia B (Factor IX deficiency). Treatments can come in the form of injections, which help a patient replace the clotting factor their bodies won’t produce.

Existing treatment is limited for hemophilia patients in the developing world.

Working Together to Treat Hemophilia

Direct Relief has provided many tens of millions of cold-chain Factor prescription products to its numerous healthcare partners that assist or treat hemophiliac patients in in the developing world. These treatments prevent severe external or internal bleeding that can take place without these crucial medicines.

Direct Relief collaborates with healthcare manufacturing partners that provide it donations of Factor therapies, which include Bayer, Bioverativ, Pfizer, and Shire. Direct Relief provides these products to its Overseas Hemophilia Support Network, which consists of hospitals and foundations in over 30 countries of the developing world that treat children or adults with hemophilia.

Direct Relief also operates an extensive medicine access program for children in the United States that attend special summer camps aimed at educating them on how to manage the disease. Direct Relief has for years provided therapies to these young people so they can experience normal summer activities in a safe environment. For the continued success of the program, Direct Relief annually partners with Pfizer to provide requested and required quantities of Factor VIII and Factor IX to its network of hemophilia summer camp programs.

Giving is Good Medicine

You don’t have to donate. That’s why it’s so extraordinary if you do.